Jordan Peterson prompts MISSD to seek akathisia warnings
MISSD called on May 1, 2026, for better drug risk disclosure and stronger clinician awareness after renewed media attention involving jordan peterson and akathisia. The Medication-Induced Suicide Prevention and Education Foundation in Memory of Stewart Dolin said clearer warnings and more accurate recognition are needed to prevent harm.
Wendy Dolin said akathisia is not clearly disclosed in current drug labeling, which she said contributes to delayed recognition and misdiagnosis. She also said, "Clear warnings and accurate recognition are essential to preventing harm."
Jordan Peterson and akathisia
Public accounts shared by Mikhaila Peterson say Jordan Peterson has experienced symptoms consistent with akathisia. Stacey Haza, an akathisia survivor, launched a Change.org petition calling for black box warnings that explicitly name and describe the condition.
Black box warnings are the U.S. Food and Drug Administration’s most serious safety warnings. MISSD’s push is aimed at making akathisia visible on labels and in clinical practice, rather than leaving patients to connect the symptoms after treatment has already started.
Stacey Haza and drug labeling
Haza said she was misdiagnosed and mistreated after developing akathisia. She said, "I just remember that things weren’t right. I felt like I was crawling out of my skin. I was afraid of literally everything."
She also said, "In the prescribed harm community, one of the things you hear over and over is, 'I wish someone had told me—I wish I had known.'" An online platform, prescribed-harm.com, has been created where individuals can share their experiences.
Hundreds of medications
MISSD describes akathisia as a medication-induced neuropsychiatric disorder that can involve severe inner agitation, an inability to sit still, panic, insomnia, and intense psychological distress. In severe cases, it has been associated with self-harm, violence, and suicide, and it may occur with or without visible movement.
The foundation says akathisia is frequently misdiagnosed as an underlying psychiatric condition rather than recognized as an adverse drug effect. It says the condition has been associated with hundreds of medications, including dopamine-blocking drugs, certain anti-nausea drugs, some anti-infective and antimalarial medications, antidepressants, antipsychotics, certain acne or hair-loss treatments, and other central nervous system medications.
For patients and caregivers, the practical step is to treat new agitation, inability to sit still, insomnia, or severe distress after a medication change as something to raise quickly with a clinician. MISSD’s message is straightforward: the warning has to reach the label and the exam room before the reaction is mistaken for something else.
